Literature DB >> 33789293

Increased Incidence of Stroke and Transient Ischemic Attack in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis in Germany.

Kathleen Trömmer1, Karel Kostev2, Louis Jacob3, Christian Tanislav4.   

Abstract

BACKGROUND: As chronic inflammatory diseases may be associated with an increased risk of vascular events, the aim of the present study was to assess the incidence of stroke and transient ischemic attack (TIA) in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS).
METHODS: Patients diagnosed with RA and AS in 1,262 general practices in Germany between 2000 and 2015 were selected. RA and AS patients were matched to patients without RA or AS using propensity scores based on age, sex, physician, co-diagnoses, and co-therapies. The Kaplan-Meier curves and Cox regression models were used to study the incidence of stroke and TIA as a function of RA and AS.
RESULTS: In the study population (N = 29,106; mean age 54.8 years; 65% women), 24,580 patients had RA and 4,526 had AS. RA was significantly associated with the stroke (hazard ratio [HR] = 1.42, confidence interval [CI]: 1.25-1.60) and TIA (HR = 1.69, CI: 1.46-1.95). The association between RA and stroke was strongest in the age group 18-40 years (HR = 3.45, CI: 1.30-9.18). The HR for stroke in AS was 1.41 (CI: 0.99-2.00) and for TIA 1.62 (1.08-2.44).
CONCLUSION: RA was significantly associated with stroke and TIA, with young patients being at a particularly increased risk. AS was tendentially associated with stroke and TIA.
© 2021 S. Karger AG, Basel.

Entities:  

Keywords:  Ankylosing spondylitis; Cohort studies; Rheumatoid arthritis; Stroke; Transient ischemic attack

Year:  2021        PMID: 33789293     DOI: 10.1159/000514889

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  1 in total

1.  No increased incidence of venous thrombosis or pulmonary embolism after SARS-CoV-2 vaccination in Germany.

Authors:  C Tanislav; J Rosenbauer; R Zingel; K Kostev
Journal:  Public Health       Date:  2022-03-16       Impact factor: 4.984

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.